Fund flows: Biotech stocks cannot perform well if investors pull more money out of the sector than they put in. That's what happened for most of 2016. Fund flows into biotech picked up after the election in November. Watch this trend and hope it.
Is there more left in the current run-up? Several things would suggest the answer is yes.
Figures 1 and 2 show the five best and worst rated ETFs and mutual ... is the top-rated Health Care mutual fund. Both earn an Attractive rating. The BioShares Biotechnology Products ETF (BBP) is the worst rated Health Care ETF and the Prudential Jennison.
The biggest coffers are held by pension funds, mutual funds, and insurance companies ... Especially in an expanding global economy when equities still offer the best risk/reward compared to other asset classes. But the old rules about sector rotation.
5 Reasons Why Biotech ETFs are Soaring Zacks.com.
XAutoplay: On | Off The tech giant was joined by a slew of medical sector stocks, including managed care providers UnitedHealth (UNH) and Aetna (AET), as well as leading biotech companies Celgene (CELG) and Regeneron (REGN). Defense contractors.
Biotech behemoths are enjoying a similar bull run, with Amgen Inc. (AMGN - Free Report) and Gilead Sciences Inc. (GILD - Free Report) rallying a respective 5.9% and 0.4% this year. 4 Best Biotech Mutual Funds to Buy Now.
Among the noteworthy observations about the best-performing mutual funds is the fact that the ... this list of top-performing funds includes a mutual fund focused on the rapidly growing biotechnology sector. In fact, if the list was extended, it would.
Healthcare was the second- best performing sector among the 11 major S&P 500 sectors in the first half of this year. The sector was in focus mainly because of the “Repeal and Replace Obamacare” scenario. Despite multiple attempts, the Trump-led .
quot;CFRA Equity Analyst Jeff Loo, CFA believes the outperformance is attributable to several macro factors as well as operational improvements across various sub-industries," said CFRA Director of ETF and Mutual Fund Research Todd Rosenbluth in the note.